biotech · PIK3CA Mutation · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation · RLAY
Relay Therapeutics
Relay Therapeutics is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker RLAY. Primary therapeutic focus areas include PIK3CA Mutation, PIK3CA Related Overgrowth Spectrum and Malformat
Cambridge, USA HQ
2016 Founded
211 Employees
Public company Type
RLAY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2016
- Employees
- 211
- Programs
- 6
- Drugs
- 7
- Patents
- 12
RLY-2608
Phase 2 · small molecule · PIK3CA-Related Overgrowth Spectrum (PROS)
RLY-2608 for PIK3CA-Related Overgrowth Spectrum (PROS) is a Phase 2 program (small_molecule) at Relay Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code RLY-2608-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Relay Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- PIK3CA-Related Overgrowth Spectrum (PROS)
- Status
- active
- Trials
- 1